From 1 December 2011 the Pharmaceutical Benefits Scheme listing of the fixed-dose combination of budesonide 400 micrograms with eformoterol 12 micrograms (400/12; Symbicort Turbuhaler) for asthma will be extended to include symptomatic treatment of moderate to severe chronic obstructive pulmonary disease (COPD).1
Under the new listing, budesonide with eformoterol (400/12) cannot be prescribed to initiate bronchodilator therapy for COPD.
The extended listing applies to adults with forced expiratory volume in 1 second (FEV1) ≤ 50% of predicted normal, with frequent symptoms despite long-acting bronchodilator use and/or a history of recurrent exacerbations.1
The listing does not apply to the fixed-dose combination of budesonide with eformoterol 100/6 or 200/6 inhalers.
The PBAC recommended the listing on a cost-minimisation basis — that is similar efficacy and cost — compared with fluticasone 250 micrograms with salmeterol 25 micrograms. The equi-effective doses are fluticasone 500 micrograms with salmeterol 50 micrograms twice daily, and budesonide 400 micrograms with eformoterol 12 micrograms twice daily.
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.
